Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Quoin Pharmaceuticals  / Equity Bottom-Up

<ul><li> In Dec.</li><li>2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the safety and efficacy of twice-daily application of QRX003 to more than 80% of the body surface area in NS patients, an application dosage QNRX anticipates in real-world usage if QRX003 obtains regulatory approval.</li><li>This represents the most extensive clinical application of QRX003 thus far.</li></ul>

 In Dec.2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the safety and efficacy of twice-daily application of QRX003 to more than 80% of the body surface area in NS patients, an application dosage QNRX anticipates in real-world usage if QRX003 obtains regulatory approval.This represents the most extensive clinical application of QRX003 thus far.

QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26